C4X shows being early to the party can bring success
Very early stage deals could be the way for C4X to avoid the funding desert that has scuppered so many other UK biotechs.
Amid Immunocore’s C-suite bloodletting Glaxo provides solace
Immunocore has recently been beset with multiple senior executive departures, but has managed to press on into phase I with a Glaxo-partnered asset.
